Morquio syndrome (referred to as mucopolysaccharidosis IV or Morquio) is a mucopolysaccharide storage disease (see also lysosomal storage disorder), usually inherited. It is a relatively rare dwarfism with serious consequences. Comes from parents that produce one gene of it, even normal healthy parents. When the body cannot process certain types of mucopolysaccharides, they build up or are eliminated, causing various symptoms.
Type A is a deficiency of the enzyme N-acetylgalactosamine-6-sulfate sulfatase.
Type B is a deficiency of the enzyme beta-galactosidase.
History
The condition was first described, simultaneously and independently, in 1929, by Luis Morquio in Montevideo, Uruguay, and by James Frederick Brailsford in Birmingham, England. They both recognized the occurrence of corneal clouding, aortic valve disease, and urinary excretion of keratan sulfate. Morquio observed the disorder in 4 siblings in a family of Swedish extraction and reported his observations in French.
Symptoms
The following symptoms are associated with Morquio syndrome:
Abnormal heart development
Abnormal skeletal development
Hypermobile joints
Large fingers
Knock-knees
Widely spaced teeth
Coarse facial features
Large head
Bell shaped chest (ribs flared)
Compression of spinal cord
Death (When heart is too big for body)
Dwarfism ( when a person is very small)
Laboratory diagnosis
As most mucopolysaccharidoses, Morquio syndrome exhibits alterations in white blood cells that are diagnostic, and might allow for screening procedures and cost-effective differential diagnosis in the future. These anomalies can be best studied with Wright stain, the routine dye employed in hematology laboratory. Neutrophils in Morquio's syndrome exhibit persistence of the azurophilia in its granules, which is explained by the deficient enzyme's inability to clear them from mucopolysaccharides used as a tags in the cells vesicular sorting system. Approximately 70 percent of the neutrophils exhibit this subtle alteration. Differential diagnosis must be made with mucopolisaccharidoses I,II,III,VI and VII.
Nonetheless, after this screening procedure has been carried on, quantitative enzyme determination assays must be conducted to verify the diagnosis, should any replacement treatment is available.
Complications
Complications that may develop include:[citation needed]
Heart failure
Difficulty with vision
Walking problems related to abnormal curvature of the spine
Abnormal neck bones can cause spinal cord damage that can cause severe disease including paralysis if not caught early -- spinal fusion can prevent this